SynOx Therapeutics has completed subject enrolment in its multi-centre Phase III TANGENT trial of the humanised IgG1 ...

The KIT inhibitors market remains highly competitive, driven by established players such as ONO Pharmaceutical and Blueprint Medicines, among others. At the same time, companies like Celldex ...

The drug targets the overgrowth of synovial cells and inflammatory components that drive tumor development and joint ...

Vimseltinib is the first and only therapy with a positive CHMP opinion for the treatment of TGCT in the European Union Deciphera Pharmaceuticals, LLC, a biopharmaceutical company focused on discoverin ...

Deciphera Pharmaceuticals, LLC, a biopharmaceutical company focused on discovering, developing, and commercializing important ...

The tumor cells closest to the lung, the most nutrient-dense region, were the most fit, meaning their lineage history indicated the highest rate of cell division over time.

NEW YORK – Vir Biotechnology on Thursday said it has started treating patients in a Phase I trial of its T-cell engager, VIR-5525, with or without Merck's Keytruda (pembrolizumab) in patients with ...

INTRODUCTION Giant cell arteritis (GCA) is the most frequent primary systemic vasculitis in adults, involving medium-to-large-sized vessels. It occurs almost exclusively in individuals over the age of ...

ASCO 2025 showcased breakthroughs in sarcoma treatment, emphasizing precision medicine, immunotherapy, and promising new ...